Cascione L - Search Results

1

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.

Spriano F, Sartori G, Tarantelli C, Barreca M, Golino G, Rinaldi A, Napoli S, Mascia M, Scalise L, Arribas AJ, Cascione L, Zucca E, Stathis A, Gaudio E, Bertoni F. Spriano F, et al. Among authors: cascione l. EJHaem. 2022 Jul 27;3(3):764-774. doi: 10.1002/jha2.535. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051080 Free PMC article.

2

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L. Chilà R, et al. Among authors: cascione l. Oncotarget. 2015 Feb 20;6(5):3394-408. doi: 10.18632/oncotarget.2583. Oncotarget. 2015. PMID: 25428911 Free PMC article.

3

DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Briere J, Forconi F, Zamò A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat G, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F. Arribas AJ, et al. Among authors: cascione l. Blood. 2015 Mar 19;125(12):1922-31. doi: 10.1182/blood-2014-08-596247. Epub 2015 Jan 22. Blood. 2015. PMID: 25612624 Free PMC article.

4

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. Boi M, et al. Among authors: cascione l. Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26. Clin Cancer Res. 2015. PMID: 25623213

5

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.

Mensah AA, Kwee I, Gaudio E, Rinaldi A, Ponzoni M, Cascione L, Fossati G, Stathis A, Zucca E, Caprini G, Bertoni F. Mensah AA, et al. Among authors: cascione l. Oncotarget. 2015 Mar 10;6(7):5059-71. doi: 10.18632/oncotarget.3239. Oncotarget. 2015. PMID: 25671298 Free PMC article.

6

The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.

Bernasconi E, Gaudio E, Kwee I, Rinaldi A, Cascione L, Tarantelli C, Mensah AA, Stathis A, Zucca E, Vesci L, Giannini G, Bertoni F. Bernasconi E, et al. Among authors: cascione l. Br J Haematol. 2015 Nov;171(3):378-86. doi: 10.1111/bjh.13595. Epub 2015 Aug 3. Br J Haematol. 2015. PMID: 26235926 Free article.

7

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.

Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, Bertoni F. Gaudio E, et al. Among authors: cascione l. Ann Oncol. 2016 Jun;27(6):1123-1128. doi: 10.1093/annonc/mdw131. Epub 2016 Mar 8. Ann Oncol. 2016. PMID: 26961147 Free article.

8

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F. Gaudio E, et al. Among authors: cascione l. Oncotarget. 2016 Sep 6;7(36):58142-58147. doi: 10.18632/oncotarget.10983. Oncotarget. 2016. PMID: 27494885 Free PMC article.

9

Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.

Gobba S, Moccia AA, Gulden-Sala W, Conconi A, Diem S, Cascione L, Iacoboni G, Margiotta-Casaluci G, Aprile von Hohenstaufen K, Stathis A, Hitz F, Pinotti G, Gaidano G, Zucca E. Gobba S, et al. Among authors: cascione l. Hematol Oncol. 2018 Feb;36(1):84-92. doi: 10.1002/hon.2447. Epub 2017 Jun 16. Hematol Oncol. 2018. PMID: 28621491

10

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F. Bernasconi E, et al. Among authors: cascione l. Br J Haematol. 2017 Sep;178(6):936-948. doi: 10.1111/bjh.14803. Epub 2017 Jun 27. Br J Haematol. 2017. PMID: 28653353 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

125 results

Search Page